Uncategorized

Seres Therapeutics, Inc. and Nestlé Health Science announced the presentation of a post-hoc analysis from the Phase 3 development program for VOWST™, the first and only U.S. Food and Drug Administration -approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI.

Bristol Myers Squibb announced the first disclosure of primary analysis results from two pivotal studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi in patients with relapsed or refractory follicular lymphoma and the relapsed or refractory mantle cell lymphoma cohort of TRANSCEND NHL 001, an open-label, multicenter, Phase 1, single-arm, seamless-design

The Bespoke Gene Therapy Consortium intends to bring AAV-based gene therapies to patients whose diseases are often ignored by commercial interests.

Jubilant Therapeutics’s differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

Scott Rivers, president and managing partner of an executive search and talent branding firm, weighs in on what managers can do to keep top talent.

Es una infección común de la piel que ha resultado en un aumento de las hospitalizaciones y los costos

La impresión 3D ha revolucionado la forma en que fabricamos objetos, permitiéndonos crear diseños personalizados y funcionales de manera accesible. Uno de los elementos clave en este proceso son los filamentos, los materiales utilizados para alimentar las impresoras 3D. A la hor …

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.

The stock deal aims to strengthen Coherus Biosciences’ position in the field of cancer therapeutics and expand its product portfolio.

Pent-up demand for healthcare delayed during COVID-19 is making a reappearance, pressuring medical costs for health insurers that had a financial windfall during the pandemic.